Evidence map›Paper›PMID 41236657›Full record

ArticleEuropean radiology2026

Ablation for hepatocellular carcinoma in hepatitis B-related recompensated vs. compensated cirrhosis.

Hang Zheng, Qiqi Liu, Nijin Wu, Zhaojuan Wu, Can Zhang, Yuemin Feng, Chenyi Liu, Xinya Zhao, Qiang Zhu, Fujun Yu

Abstract readMulticenter StudyComparative Study
PubMed Publisher
In one paragraph

Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hang Zheng *Department of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qiqi Liu *Cheeloo College of Medicine, Shandong University, Jinan, China.
Nijin Wu *Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Zhaojuan WuCheeloo College of Medicine, Shandong University, Jinan, China.
Can ZhangDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yuemin FengDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Chenyi LiuDepartment of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Xinya ZhaoDepartment of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Qiang ZhuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. zhuqiang@sdu.edu.cn.
Fujun YuDepartment of Gastroenterology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. yufujun@wmu.edu.cn.ORCID http://orcid.org/0000-0001-5321-7228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the efficacy and safety of ablation therapy in hepatocellular carcinoma (HCC) patients with hepatitis B-related compensated cirrhosis versus those with recompensated cirrhosis. MATERIALS AND

methodsIn this multicenter, retrospective cohort study, we enrolled hepatitis B-related HCC patients (73 with recompensated cirrhosis and 666 with compensated cirrhosis) who underwent ablation between January 2009 and February 2024. Propensity score matching was performed to balance baseline characteristics, resulting in 73 matched pairs. Recurrence-free survival (RFS), overall survival (OS), and complications were compared.

resultsA total of 739 patients (median age, 59 years [interquartile range, 53-66 years]; 579 men [78.2%]) were enrolled. Following propensity score matching procedures, no significant difference in major complications was observed between patients with recompensated cirrhosis and those with compensated cirrhosis (6.8% vs. 2.7%, p = 0.438). Critically, no postoperative liver failure or decompensation events occurred after ablation therapy in patients with either recompensated cirrhosis or compensated cirrhosis. Moreover, RFS was comparable between patients with recompensated cirrhosis and those with compensated cirrhosis (73.7% vs. 74.0% at 1 year; 43.3% vs. 43.2% at 3 years; 24.8% vs. 36.9% at 5 years; p = 0.699). The overall survival rates at 1, 3, and 5 years were 97.3%, 84.5%, and 73.4% in patients with recompensated cirrhosis, and 98.6%, 92.7%, and 83.7% in patients with compensated cirrhosis, respectively (p = 0.363).

conclusionsAblation therapy is effective and safe in HCC patients with hepatitis B-related recompensated cirrhosis, representing a viable curative option for these patients. KEY POINTS: Question Is ablation as safe and effective for patients with hepatitis B-related recompensated cirrhosis as it is for those with compensated cirrhosis? Findings The incidence of major complications and long-term survival did not differ statistical significantly between patients with hepatitis B-related recompensated cirrhosis and those with compensated cirrhosis. Clinical relevance Ablation therapy is effective and safe in hepatocellular carcinoma patients with hepatitis B-related recompensated cirrhosis, representing a viable curative option for these patients.

Indexed as

Carcinoma, HepatocellularCatheter AblationHepatitis BLiver CirrhosisLiver NeoplasmsAgedFemaleHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesTreatment OutcomeAblation techniquesCirrhosisHepatitis B virusHepatocellular carcinoma

Identifiers

PMID41236657

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.